Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

April 8, 2026

Egetis Receives Conditional FDA Acceptance of Proprietary Name Emcitate®

Read more

Regulatory

March 27, 2026

Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency

Read more

Regulatory

March 24, 2026

Egetis Therapeutics’ Annual Report 2025 published

Read more

Upcoming event

April 14, 2026

Annual General Meeting

Latest presentation

March 11, 2026

Leerink Global Healthcare Conference

Latest Report

February 26, 2026

Full year report 2025

Calendar and upcoming reports

April 14, 2026

Annual General Meeting

April 16, 2026

van Lanschot Kempen Life Sciences Conference (Amsterdam)

April 29, 2026 (7:00am CEST)

Interim Report Q1 2026

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]